Free Trial
NASDAQ:XOMA

XOMA Royalty Q1 2024 Earnings Report

XOMA Royalty logo
$33.77 -0.43 (-1.26%)
Closing price 08/25/2025 04:00 PM Eastern
Extended Trading
$34.53 +0.76 (+2.25%)
As of 08/25/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Royalty EPS Results

Actual EPS
-$0.86
Consensus EPS
-$0.71
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$1.49 million
Expected Revenue
$0.96 million
Beat/Miss
Beat by +$530.00 thousand
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

XOMA Royalty's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Royalty Earnings Headlines

Analysts Set Expectations for XOMA Royalty FY2026 Earnings
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.tc pixel
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Royalty Profile

More Earnings Resources from MarketBeat